PMID- 26806698
OWN - NLM
STAT- MEDLINE
DCOM- 20161017
LR  - 20201209
IS  - 2042-7158 (Electronic)
IS  - 0022-3573 (Linking)
VI  - 68
IP  - 1
DP  - 2016 Jan
TI  - Wild ginseng cambial meristematic cells ameliorate hepatic steatosis and 
      mitochondrial dysfunction in high-fat diet-fed mice.
PG  - 119-27
LID - 10.1111/jphp.12487 [doi]
AB  - OBJECTIVES: The aim of this study was to determine the protective mechanisms of 
      wild ginseng cambial meristematic cells (CMCs) on non-alcoholic fatty liver 
      disease in high-fat diet (HFD)-fed mice. METHODS: Male C57BL/6 mice received 
      either normal-fat diet or HFD for 10 weeks along with wild ginseng CMCs (75, 150 
      and 300 mg/kg) or vehicle (0.5% carboxyl methyl cellulose) by oral administration 
      once a day. Triglyceride and total cholesterol contents were measured in liver 
      and serum samples. Parameters for hepatic lipid metabolism and mitochondria 
      biogenesis were assessed. KEY FINDINGS: Treatment with wild ginseng CMCs markedly 
      attenuated body weight, serum and hepatic lipid contents, and serum 
      aminotransferase activity. While wild ginseng CMCs attenuated the increases in 
      sterol regulatory element-binding transcription factor 1 (SREBP-1) and 
      carbohydrate-responsive element-binding protein (ChREBP) expression, it enhanced 
      the increases in carnitine palmitoyltransferase 1A (CPT1A) and peroxisome 
      proliferator-activated receptor alpha (PPAR-alpha) expression. HFD decreased 
      glutamate dehydrogenase activity and glutathione content, and increased lipid 
      peroxidation, which were all attenuated by wild ginseng CMCs. Furthermore, wild 
      ginseng CMCs enhanced mitochondrial biogenesis-related factors, including 
      peroxisome proliferator-activated receptor-gamma co activator 1alpha (PGC1alpha), nuclear 
      respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM). 
      CONCLUSIONS: Wild ginseng CMCs protect against HFD-induced liver injury, which 
      prevents lipid accumulation and mitochondrial oxidative stress, and enhances 
      mitochondrial biogenesis.
CI  - (c) 2015 Royal Pharmaceutical Society.
FAU - Lee, Sang-Bin
AU  - Lee SB
AD  - School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
FAU - Cho, Hong-Ik
AU  - Cho HI
AD  - School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
FAU - Jin, Young-Woo
AU  - Jin YW
AD  - Plant Stem Cell Institute, Unhwa Corp., Jeonju, Republic of Korea.
FAU - Lee, Eun-Kyong
AU  - Lee EK
AD  - Plant Stem Cell Institute, Unhwa Corp., Jeonju, Republic of Korea.
FAU - Ahn, Jeung Youb
AU  - Ahn JY
AD  - Plant Stem Cell Institute, Unhwa Corp., Jeonju, Republic of Korea.
FAU - Lee, Sun-Mee
AU  - Lee SM
AD  - School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
LA  - eng
SI  - GENBANK/D12492
SI  - GENBANK/S10026
SI  - GENBANK/V10001
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Basic Helix-Loop-Helix Leucine Zipper Transcription Factors)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (High Mobility Group Proteins)
RN  - 0 (Mlxipl protein, mouse)
RN  - 0 (Nrf1 protein, mouse)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Nuclear Respiratory Factor 1)
RN  - 0 (PPAR alpha)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Sterol Regulatory Element Binding Protein 1)
RN  - 0 (Tfam protein, mouse)
RN  - 0 (Transcription Factors)
RN  - 0 (Triglycerides)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - EC 2.3.1.21 (Carnitine O-Palmitoyltransferase)
RN  - EC 2.6.1.- (Transaminases)
RN  - GAN16C9B8O (Glutathione)
SB  - IM
MH  - Animals
MH  - Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
MH  - Body Weight/drug effects
MH  - Carnitine O-Palmitoyltransferase/metabolism
MH  - Cholesterol/blood/metabolism
MH  - DNA-Binding Proteins/metabolism
MH  - Diet, High-Fat/*adverse effects
MH  - Fatty Liver/blood/*drug therapy/metabolism
MH  - Glutathione/metabolism
MH  - High Mobility Group Proteins/metabolism
MH  - Lipid Metabolism/drug effects
MH  - Lipid Peroxidation/drug effects
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mitochondrial Diseases/blood/*drug therapy/metabolism
MH  - Non-alcoholic Fatty Liver Disease/blood/drug therapy/metabolism
MH  - Nuclear Proteins/metabolism
MH  - Nuclear Respiratory Factor 1/metabolism
MH  - Organelle Biogenesis
MH  - PPAR alpha/metabolism
MH  - Panax/*chemistry
MH  - RNA-Binding Proteins/metabolism
MH  - Sterol Regulatory Element Binding Protein 1/metabolism
MH  - Transaminases/metabolism
MH  - Transcription Factors/metabolism
MH  - Triglycerides/blood
OTO - NOTNLM
OT  - de-novo lipogenesis
OT  - mitochondrial biogenesis
OT  - non-alcoholic fatty liver disease
OT  - wild ginseng cambial meristematic cells
OT  - beta-oxidation
EDAT- 2016/01/26 06:00
MHDA- 2016/10/19 06:00
CRDT- 2016/01/26 06:00
PHST- 2015/05/28 00:00 [received]
PHST- 2015/09/12 00:00 [accepted]
PHST- 2016/01/26 06:00 [entrez]
PHST- 2016/01/26 06:00 [pubmed]
PHST- 2016/10/19 06:00 [medline]
AID - 10.1111/jphp.12487 [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 2016 Jan;68(1):119-27. doi: 10.1111/jphp.12487.